As Chief Scientific Officer at Aspect Biosystems, Sam is responsible for our scientific innovation and development. He co-founded the company in 2013 and currently leads our technical efforts in developing cell-containing bioprinted tissues to treat currently incurable diseases. In 2023, based on highly promising pre-clinical data, Aspect partnered with Novo Nordisk to co-develop bioprinted tissue therapeutics for diabetes and obesity. This deal, worth up to $2.6Bn + royalties, is the largest bioprinting deal ever and one of the largest pre-clinical deals in Canadian history. Sam holds a PhD in respiratory cell biology from the University of Nottingham.